32431-83-7Relevant academic research and scientific papers
Fluorinated Dithienylethene-Naphthalenediimide Copolymers for High-Mobility n-Channel Field-Effect Transistors
Chen, Zhihui,Zhang, Weifeng,Huang, Jianyao,Gao, Dong,Wei, Congyuan,Lin, Zuzhang,Wang, Liping,Yu, Gui
, p. 6098 - 6107 (2017)
We develop two donor-acceptor copolymers based on a fluorinated dithienylethene building block, namely PNFDTE1 and PNFDTE2, in which naphthalenediimide (NDI) acts as an acceptor unit. Thermogravimetric analysis displayed both copolymers having good thermal stability with high decomposition temperatures over 400 °C. Broad absorption spectra were observed in the UV-vis-NIR region, with the absorption maxima being 720 and 724 nm for PNFDTE1 and PNFDTE2, respectively. Cyclic voltammetry tests exhibited deep-lying lowest unoccupied molecular orbital energy levels of ca. -4.0 eV. Two-dimensional grazing incidence X-ray diffraction patterns showed that different packing modes for two polymers result in the variation in charge transport properties. Backbone fluorination effectively decreases electron injection barrier, thereby facilitating electron mobility. An impressive electron mobility of 3.20 cm2 V-1 s-1 was achieved in air for PNFDTE1-based polymer field-effect transistors fabricated on the poly(ethylene terephthalate) substrate. The mobility value is almost the highest for NDI-containing polymers on the flexible substrate. This work provides a guideline for design and synthesis of fluorinated semiconductors that enables control of charge-transport polarity.
TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE
-
Page/Page column 81; 83, (2015/06/08)
The present invention relates to compounds of the formula (I), wherein R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to thei
TRICYCLIC PIPERIDINE COMPOUNDS
-
Page/Page column 111-112; 115, (2015/06/08)
The present invention relates to compounds of the formula (I), wherein R, R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.
Nitrogen containing heterocyclic compounds and medicines containing the same
-
, (2008/06/13)
Compounds represented by the following general formula: (wherein X1, X2, X3 and X4 each independently represent a single bond, C1-6 alkylene, etc.; A2 represents optionally substituted phenyl, etc.; A1 represents an optionally substituted 5- to 7-membered heterocyclic group containing —C(═Q1)— (wherein Q1 represents oxygen, sulfur or ═N—R11 (wherein R11 represents hydrogen or C1-6 alkyl)) and nitrogen, etc.; and Z1 represents piperidin-diyl, etc.), salts thereof and hydrates of the foregoing.
